YOLFTbeta
Microba Life Sciences Ltd

Microba Life Sciences Ltd

MAP · AU · Healthcare / Diagnostics & Research

0.036AUD+0.00 (+2.86%)

Price History

Full chart

Market Stats

Previous Close0.035
Open0.035
Day Range0.035 – 0.036
52-Week Range0.036 – 0.105
Volume82.64K
Market Cap34.32M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.03
Dividend Yield0.00%
Beta2.10
50-Day Avg0.0518
200-Day Avg0.0658

About

Microba Life Sciences Limited provides microbiome testing, supplements, and analysis services in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, the United States, Asia, and Ireland. It operates through, Testing Services and Supplements, and Research and Development segments. The company also develops pathology, therapeutics, and diagnostics services based on the human gut microbiome. In addition, it offers MetaPanel, a metagenomic test for pathogen detection; microba microbiome explorer; research testing services; and data-driven therapeutics platform that develops therapies for ulcerative colitis, inflammatory bowel autoimmune diseases, oncology, and allergy. Microba Life Sciences Limited was incorporated in 2017 and is based in Brisbane, Australia.

Company Details

  • SectorHealthcare
  • IndustryDiagnostics & Research
  • CEODr. Luke Reid
  • Employees0
  • Headquarters324 Queen Street, Brisbane, QLD, Australia, 4000, Australia
  • Websitehttps://microba.com

Leadership

  • Prof. Gene TysonCo-Founder & Non-Executive Director
  • Mr. James HeathCFO & Company Secretary
  • Dr. Luke ReidChief Executive Officer (Leave of Absence)
  • Prof. Philip HugenholtzCo-Founder & Chair of Scientific Advisory Board
  • Dr. David WoodChief Technology Officer
  • Prof. Lutz KrauseChief Scientific Officer
  • Dr. Nicola AngelHead of Laboratory Operations & Laboratory Director
  • Mr. Keith ByrneHead of Test Operations
  • Eric DaviesChief Revenue Officer
  • Mr. Alaster Stockwell-JonesManaging Director of UK

Financials

Income Statement

Currency: AUD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue1.83M2.91M3.73M4.69M5.42M12.09M15.67M14.76M
Growth (%)-+59.12%+28.31%+25.62%+15.60%+123.06%+29.60%-5.81%
Cost of Revenue4.32M6.96M9.04M2.32M12.19M6.18M8.23M26.50M
Gross Profit-2.49M-4.05M-5.30M2.37M-6.77M5.91M7.44M-11.74M
Gross Margin-136.21%-139.32%-142.12%50.46%-124.96%48.85%47.49%-79.54%
Operating Expense2.30M3.35M4.27M18.64M13.45M32.75M32.05M8.57M
Operating Income-4.79M-7.41M-9.57M-16.27M-20.23M-26.84M-24.61M-20.30M
Operating Margin-261.96%-254.59%-256.41%-347.05%-373.18%-222.02%-157.05%-137.58%
EBITDA-3.93M-5.53M-6.28M-9.86M-17.07M-17.10M-10.51M-15.89M
EBITDA Margin-215.06%-190.07%-168.31%-210.36%-314.88%-141.45%-67.08%-107.69%
Net Income-4.73M-6.65M-7.52M-11.47M-12.68M-19.94M-14.94M-20.72M
Net Income Margin-258.94%-228.62%-201.58%-244.64%-233.95%-164.92%-95.34%-140.40%
R&D-163.27K1.54M5.38M9.34M10.84M2.01M417.06K
R&D as % of Total Revenue-5.61%41.24%114.83%172.27%89.63%12.82%2.83%
Interest Expense24.03K36.97K23.46K55.29K60.41K69.22K176.69K238.56K
Interest Expense % of Total Revenue1.31%1.27%0.63%1.18%1.11%0.57%1.13%1.62%

Balance Sheet

Currency: AUD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets13.99M10.81M18.49M39.48M46.95M58.04M47.44M39.81M
Total Liabilities1.43M3.10M3.55M5.94M8.23M16.82M14.94M13.70M
Total Equity12.56M7.70M14.94M33.54M38.57M41.22M32.49M24.38M
Cash11.00M6.90M13.03M30.58M32.04M20.89M11.74M7.95M
Total Debt406.38K563.65K269.02K1.33M1.14M1.58M3.23M4.11M
Net Debt-10.59M-6.33M-12.76M-29.26M-30.91M-19.31M-8.51M-3.84M

Cash Flow

Currency: AUD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-3.62M-4.32M-7.18M-10.45M-12.39M-15.57M-12.01M-12.37M
Investing Cash Flow-833.71K-856.17K-522.48K-1.73M-3.00M-13.95M-2.83M-3.80M
Financing Cash Flow13.72M1.08M13.84M29.22M16.68M18.39M5.58M12.76M
Capital Expenditure836.13K856.17K672.46K1.87M3.04M4.38M2.90M240.34K
Free Cash Flow-4.46M-5.18M-7.85M-1.87M-15.43M-19.95M-14.91M-12.61M
Dividends Paid---425.35K595.63K---
FCF to OCF123.09%119.80%109.36%17.92%124.50%128.13%124.14%101.94%
Dividend Paid to FCF----22.71%-3.86%---

Earnings

Report DateApr 1, 2022Aug 25, 2022Nov 30, 2022Feb 22, 2023Apr 19, 2023Aug 29, 2023Nov 5, 2023Feb 27, 2024Apr 22, 2024Aug 28, 2024Oct 28, 2024Feb 25, 2025Apr 17, 2025Aug 26, 2025Oct 27, 2025Mar 4, 2026Apr 23, 2026
EPS Estimate0.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.00
EPS Actual-0.01-0.030.00-0.020.000.000.000.000.000.000.00-0.010.00-0.020.000.000.00
Surprise-----------------
Timing-----------------

Key Statistics & Ratios

Market Cap34.32M
Enterprise Value25.69M
Trailing P/E0.00
Forward P/E0.00
Price / Sales2.33
Price / Book1.14
EPS-0.03
Book Value0.035
Revenue (TTM)14.76M
Gross Profit (TTM)7.03M
EBITDA-18.66M
Profit Margin-140.40%
Operating Margin-126.38%
Return on Equity-72.87%
Return on Assets-29.09%
Shares Outstanding700.31M
Shares Float291.00M
Beta2.10
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%